Exelixis (NASDAQ:EXEL) CFO Christopher Senner Sells 34,278 Shares

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher Senner sold 34,278 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $43.00, for a total transaction of $1,473,954.00. Following the completion of the sale, the chief financial officer directly owned 1,042,579 shares of the company’s stock, valued at $44,830,897. The trade was a 3.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Exelixis Stock Up 0.9%

Shares of NASDAQ EXEL opened at $44.47 on Thursday. The company has a market capitalization of $11.55 billion, a PE ratio of 16.05, a PEG ratio of 0.99 and a beta of 0.42. The stock’s 50 day moving average price is $43.77 and its 200-day moving average price is $41.13. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the business posted $0.55 earnings per share. Exelixis’s revenue was up 5.6% on a year-over-year basis. As a group, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Neutral Sentiment: Summary: Multiple SEC Form 4 filings show insider sales totaling roughly $9 million across several executives and directors; the filings do not state the motivation (could be pre‑planned sales, diversification, or personal liquidity). CFO Christopher Senner filings
• Negative Sentiment: CFO Christopher J. Senner sold 34,278 shares on Feb 13 at an average $43.00 (~$1.47M) and 30,617 shares on Feb 17 at $43.67 (~$1.34M); combined reduction of ~3.18% and 3.04% of his holdings in separate filings. SEC filing
• Negative Sentiment: EVP Patrick J. Haley sold 67,814 shares on Feb 17 at an average $43.52 (~$2.95M), a ~15.08% cut to his stake. SEC filing
• Negative Sentiment: Director Bob Oliver sold 30,250 shares on Feb 13 at an average $43.81 (~$1.33M), reducing his position by ~58.9%. SEC filing
• Negative Sentiment: SVP Brenda Hefti sold 18,669 shares on Feb 18 at an average $44.01 (~$0.82M), trimming her holding by ~16.2%. SEC filing
• Negative Sentiment: Director Sue Gail Eckhardt sold 3,856 shares on Feb 13 at an average $43.79 (~$0.17M), an ~18.0% reduction of her stake. SEC filing

Institutional Investors Weigh In On Exelixis

Several institutional investors have recently made changes to their positions in the stock. Richardson Financial Services Inc. lifted its holdings in Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC lifted its holdings in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after buying an additional 500 shares in the last quarter. Motiv8 Investments LLC bought a new position in shares of Exelixis in the fourth quarter valued at approximately $26,000. Root Financial Partners LLC bought a new stake in Exelixis during the 3rd quarter worth approximately $28,000. Finally, Acumen Wealth Advisors LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXEL. HC Wainwright increased their price target on shares of Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Wells Fargo & Company boosted their target price on shares of Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Oppenheimer restated a “market perform” rating and set a $36.00 price target on shares of Exelixis in a research note on Wednesday, November 5th. Royal Bank Of Canada lifted their price target on shares of Exelixis from $45.00 to $46.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 11th. Finally, Bank of America downgraded Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective on the stock. in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $47.11.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.